While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.

Research on generic drug coverage in Medicare Part D plans finds access unobstructed for majority of lower cost alternatives. However, study may offer incomplete picture, generic and biosimilar advocates say.

Almost a third of Medicare drug plans are expected to offer the insulin demonstration next year, while almost none have signed up for the payment ‘modernization’ demo, under which plans would be at more risk for spending during the catastrophic phase. The Centers for Medicare and Medicaid Services also announces basic Part D premiums will average $30.50 for 2021.

Drug pricing experts are concerned the US government may not follow through on its commitment to pay less for COVID-19 vaccines it has helped fund given reports Moderna may be pushing a $50-$60/course price. The US also has little ability to control pricing in the private market – even for some government payers.

Industry balks at President Trump’s latest effort to force biopharma to negotiate a drug pricing solution, but investors may be pushing for concessions that could head off more onerous policies supported by a Biden White House. 

Obscure drug pricing in Europe could help minimize an “access threat” posed by US pricing policies.

Industry has 30 days to come up with a better idea that would “end foreign free riding” and close the gap between drug prices in the US and abroad, President Trump says. Administration also wants to revive rebate reform.

Industry has 30 days to come up with a better idea that would “end foreign free riding” and close the gap between drug prices in the US and abroad, President Trump says. Administration also wants to revive rebate reform.

NASEM is expected to issue a highly anticipated report in early 2021 on solutions to address Rx vial drug wastage.